Basic Info

3800 Cambridge Street
Kansas City, KS 66103
(913) 945-6756
  N/A
www.osteogenex.com
Preferred contact:
  Debra L Ellies - President/CEO
OsteoGeneX Inc
Profile last edited on: 11/18/2013
Business Identifier: bone building small molecule against the validated target Sclerostin.
Public Profile:
OsteoGeneX Inc., based in Kansas City, MO., is an early-stage biopharmaceutical company focused on becoming a worldwide leading developer and marketer of its proprietary OsteoX601. The first true oral therapeutic class of bone anabolic drugs targeting Sclerostin (SOST). Its immediate objective is to develop a first-generation small molecule therapeutic to treat moderate & severe osteoporosis. The Company is commercializing recent findings showing bone-forming osteoblasts can be modulated directly via a newly discovered ligand-receptor complex to regulate bone density in skeletal tissue. These seminal findings form the basis for OsteoGeneX's proprietary OsteoX601 Technology and its GeneX Therapeutic product platform that represents a new class of bone anabolic agents aimed at modulating the density and quality of bone for osteoporosis, skeletal fracture repair and other disorders where skeletal homeostasis is disrupted.

 Synopsis: Awardee Business Condition
Year Founded First SBIR Year 2006 Date of Last Award
Employee Range VC funded? IP Holdings
Revenue Range Private/Public Exchange/Symbol N/A : N/A
 Most Recent SBIR Projects
Year Phase Agency Dollars Project Title
Anabolic Therapeutics for Increasing Bone Denisty and Quality

      

Media coverage